ImmuCell Sees Spike in Short Interest

Biotech firm's stock sees 71.6% jump in short positions in March

Mar. 29, 2026 at 4:34am

Got story updates? Submit your updates here. ›

ImmuCell Corporation (NASDAQ:ICCC), a biotechnology company that develops and markets animal health products, saw a significant increase in short interest on its stock during March. As of March 13th, short interest totaled 27,331 shares, up 71.6% from the 15,924 shares reported on February 26th.

Why it matters

The rise in short interest could signal that some investors are betting against ImmuCell's stock performance, potentially due to concerns about the company's financial outlook or competitive position. Short interest is an important metric that can provide insights into market sentiment and potential volatility.

The details

ImmuCell's short interest now represents 0.3% of its total shares outstanding. Based on the stock's average daily trading volume of 13,770 shares, the current short interest ratio is 2.0 days, meaning it would take short sellers about 2 days to cover their positions at the current pace of trading.

  • As of March 13th, 2026, ImmuCell had 27,331 shares shorted.
  • On February 26th, 2026, ImmuCell had 15,924 shares shorted.

The players

ImmuCell Corporation

A biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. The company is headquartered in Portland, Maine.

Mesirow Financial Investment Management Inc.

A large investor that grew its position in ImmuCell by 199.6% during the 4th quarter, now owning 36,481 shares.

Steadtrust LLC

A large investor that increased its stake in ImmuCell by 79.1% in the fourth quarter, now owning 56,770 shares.

Geode Capital Management LLC

A large investor that lifted its stake in ImmuCell by 4.2% in the second quarter, now owning 71,852 shares.

Got photos? Submit your photos here. ›

The takeaway

The significant increase in short interest on ImmuCell's stock suggests that some investors are betting against the company's performance, which could lead to increased volatility in the share price. However, the stock remains rated as a 'hold' by at least one analyst, indicating a mixed outlook on the company's prospects.